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Introduction
In 2014, two independent studies reported biallelic deleterious mutations in the cat eye chromosome region 1 gene (CECR1), encoding adenosine deaminase 2 (ADA2), as the cause of a new and rare auto-inflammatory condition, named human deficiency of ADA2 syndrome (DADA2) (OMIM # 615688).
1,2 In the initial reports, DADA2 was hallmarked by recurrent episodes of fever with elevation of acute phase reactants and vasculopathy ranging from early-onset cutaneous livedo reticularis, Raynaud's phenomenon and polyarteritis to lifethreatening intracranial vasculopathy with lacunar strokes and hemorrhages. 3, 4 Bone marrow dysfunction, which may include pure red cell aplasia (PRCA), Diamond-Blackfan like anemia, thrombocytopenia and neutropenia, is now recognized as an equally important manifestation. 5, 6 In addition, immunodeficiency can be found with hypogammaglobulinemia (esp. IgM) as well as disturbances in the T cell compartment. 7 Inflammatory bowel disease, reminiscent of the bowel involvement found in patients with common variable immunodeficiency (devoid of plasma cells) can also be found. Eight of the nearly 100 DADA2 patients (8%) reported to date in the literature are deceased. 1, 2, 8, 9 The most common reason of death was stroke (in 4/8 patients). The diagnosis of DADA2 is based on the measurement of low/absent plasma ADA2 enzymatic activity and on the identification of biallelic loss-offunction mutations in CECR1, which is located within chromosome 22q11. Patients with homozygous deletions encompassing the CECR1 locus on 22q11 show the same phenotype.
Also, absent plasma ADA2 enzymatic activity has been described in singular patients with monoallelic mutations in CECR1. It is unclear at this point whether in these cases a second (cryptic) mutation is present on the other allele, in an intron, in the promoter region, or rather in a different gene affecting ADA2 expression. Alternatively copy number variations affecting the CECR1 locus may have been missed.
In humans, two ADA proteins have been described: ADA1 and ADA2. Deficiency of ADA1, encoded by the ADA gene on chromosome 20q, causes severe combined immunodeficiency
For personal use only. on October 13, 2017. by guest www.bloodjournal.org From owing to profound depletion of T, B, and NK lymphocytes, which normally show high expression of ADA1. In these patients, plasma levels of adenosine and deoxyadenosine are elevated, and their red cells show a marked accumulation of dATP (derived from deoxyadenosine). Lymphopenia has been attributed primarily to dATP pool expansion, which blocks DNA synthesis and induces apoptosis in immature lymphoid cells. Aberrant signalling via receptors for adenosine may contribute to non-immunologic features that occur in some ADA1-deficient patients. In contrast to ADA1, ADA2 is primarily expressed by myeloid cells and is mainly secreted in plasma by monocytes. 10 The function of ADA2 in cellular pathways is still enigmatic and its absence in mice has hampered investigation of pathogenic mechanisms. However, where studied, the levels of adenosine and deoxyadenosine in plasma, and of dATP in red cells, have not been elevated in DADA2. 6, [18] [19] [20] The aim of the present study is to better define the role for HSCT as a potential cure for DADA2. We report the results of a multinational cohort study of 14 patients with proven DADA2 who underwent HSCT, including the previously reported cases. All are alive, well and cured.
Patients and Methods
We conducted an international cohort study on patients with DADA2 via the European Group 
Results
We received complete data sets for 14 DADA2 patients transplanted between 2000-2016.
Patients received treatment in 11 different centers in 6 countries in Europe and North America. Five patients were reported previously. [16] [17] [18] [19] [20] [21] The male/female ratio was 8/6. The median age at initial presentation was 1.5 years (range birth to 16 years). The median age at genetic diagnosis was 10 years (range 2-25 years) ( Table 1 ). The diagnosis of DADA2 was confirmed at the molecular level by demonstration of biallelic deleterious CECR1 mutations in all patients. Plasma ADA2 enzyme activity prior to HSCT was low in 6/6 patients tested ( Yet another patient originally received myeloablative conditioning but required two unconditioned boosts following a drop in whole blood chimerism to 30%. This coincided with a decline of plasma ADA2 enzyme activity to pretransplant levels and a new presentation of auto-immune PRCA followed by agranulocytosis. Regimens were different across transplant centers. Nine patients received myeloablative conditioning and 5 received a reduced intensity regimen. The most commonly used regimen (in 5 patients) was treosulfan/fludarabine +/-thiotepa with ATG or alemtuzumab. Serotherapy was used in 12/14 patients: ATG in 4 and alemtuzumab in 8 patients. Bone marrow was the source of stem cells in 10 grafts, peripheral blood stem cells in 4. Donors were matched sibling (n=1), haplo-identical sibling (n=1), 10/10 matched unrelated (n=9), and mismatched unrelated (n=3) for the final curative transplant procedures. Methotrexate associated with a calcineurin inhibitor was the prophylactic regimen for graft-versus-host-disease in 9/14 patients ( Table 3 ). All patients received antimicrobial and graft versus host disease (GvHD) prophylaxis as per discretion of the transplant physician/center.
All patients engrafted at a median of day +20 for neutrophils and at day +23 for platelets. All patients are alive and well with a median follow-up of 18 months (range 5m-13y). All patients had resolution of the hematological and immunological phenotype and no further vascular events were reported in 13/14 patients (Figure 1) . One patient suffered from a pineal gland hemorrhage immediately post-HSCT at the time of prolonged thrombocytopenia as described earlier.
18 He has had no further vascular events since with a follow-up of 76 months.
Chimerism analysis showed full donor white blood cell chimerism in all patients. ADA2
plasma enzyme activity normalized in all patients in whom ADA2 activity was monitored post-HSCT (n=7) ( Table 2) . This occurred as early as 14 days post-HSCT, concurring with monocyte reappearance in the peripheral blood as verified by prospective monitoring of plasma ADA2 enzyme activity in 1 patient (Isabelle Meyts, unpublished observation). As for HSCT related morbidity: two patients developed veno-occlusive disease, which responded to
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Moderate chronic GvHD developed in only one patient. Viral reactivation was a frequent complication post-HSCT as it occurred in 10/14 patients. Adenoviremia was the most common in 6/14 patients (42%). The patients who developed more than 2 viral reactivations all received peripheral blood stem cells. Post-HSCT hematological autoimmune phenomena were reported in 4 of 14 patients: ITP in 2, auto-immune hemolytic anemia (AIHA) in 1 and neutropenia with immune mediated PRCA in 1, responding to various treatment regimens (high dose IVIG / steroids / sirolimus / rituximab / bortezomib / Romiplostim). Alopecia as a feature of DADA2 was present in 1 patient and completely resolved post-HSCT.
Discussion
We report the results of the first international survey on the outcome of HSCT for DADA2.
The results support the use of HSCT as a definitive cure for DADA2 with 14 out of 14 patients alive and well and 12/14 patients off all treatment at a median time post-HSCT of 18 months.
Two patients are still on immunosuppression as both are less than a year out of HSCT. HSCT proved curative for the hematological, immunological as well as vascular phenotype associated with the condition. Although the number of patients reported here is too limited to issue a general recommendation for HSCT in DADA2, the data clearly support the feasibility of HSCT as a definitive treatment option.
Importantly for all the DADA2 patients described here the indication for HSCT was the hematological and/or immunological disorder, whereas the disease emphasis in the initial reports was on the vasculopathy with livedo, polyarteritis and lacunar infarction. Indeed, PRCA, severe neutropenia, and refractory thrombocytopenia as well as combined immunodeficiency (including recurrent infection with herpesviridae) prevailed in all transplanted patients. Prior to HSCT, treatment with TNF inhibitors (etanercept, infliximab) was attempted, but proved unsuccessful in 4 patients, and interleukin-1 receptor antagonist (anakinra) failed in 2 patients as far as restoration of the hematological and immunological For personal use only. on October 13, 2017. by guest www.bloodjournal.org From phenotype was concerned. HSCT not only resolved the hematological and immunological phenotype, it also resulted in resolution of the vascular phenotype in all 6 patients who had vasculitis prior to HSCT. Only one patient experienced a single vascular event early post-HSCT at the time of severe thrombocytopenia. The same patient had an episode of late VOD, which responded to fluid restriction. No further vascular events were reported in any of the transplanted patients, in line with the current notion that the basic pathophysiology lies in macrophage skewing towards an M1 proinflammatory phenotype and that the vasculopathy phenotype can also be cured by HSCT. In this limited number of patients, no genotypephenotype correlation could be found. Therefore, the mere presence of a given mutation alone cannot support the decision to proceed to HSCT for this rare condition; rather the phenotype should be weighed in the decision to proceed to HSCT or to provide conventional treatment.
As becomes clear from our data, donor selection is important. Prior to the unravelling of the genetics of the disease, two patients received a graft from apparently healthy sibling donors who later, were shown to carry disease causing CECR1 mutations and to be ADA2 deficient, resulting in engraftment failure. The question of whether a sibling donor who carries a single deleterious mutation in CECR1 is a good option remains unclear at present. However, it can be considered safer to opt for a matched unrelated donor in these cases given that a drop in chimerism in 1 patient resulted in PRCA. Moreover at present, since absent ADA2 activity has been reported in patients with monoallelic CECR1 mutations, haplo-insufficiency of Infectious viral complications were frequent in our cohort, although they did not result in mortality. Adenovirus reactivation was the most common viral complication present in 6/14 patients (42%). This goes with previously published reports 22, 23 . Thus, frequent prospective monitoring of patients, and pre-emptive treatment is essential.
Importantly, post-HSCT hematologic autoimmune complications were common in our cohort (ITP, PRCA, AIHA, neutropenia), seen in 4/14 patients (28%). Previous reports suggested the association of post-HSCT autoimmune hematologic disorders with non-malignant disorders, unrelated donors, serotherapy, and younger age at HSCT. [24] [25] [26] In our cohort, the association with serotherapy, in particular alemtuzumab, and younger age at HSCT might represent a potential explanation. However, at present we have no solid explanation for the auto-immune phenomena post-HSCT.
In conclusion, we report the successful treatment by HSCT in 14 DADA2 patients. All patients are alive and well and cured of immunological, hematological, and vascular manifestations. For personal use only. on October 13, 2017. by guest www.bloodjournal.org From
